Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
131I-MIBG + etoposide + melphalan + carboplatin + autologous peripheral stem cell transplantation
- Development stage
- Unknown
- Lead developer
- Samsung Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This is a high-dose cancer therapy regimen combining a radiopharmaceutical (131I-MIBG) with multiple chemotherapy agents (etoposide, melphalan, and carboplatin) followed by autologous peripheral stem cell transplantation. The therapy involves: 1. **131I-MIBG**: A radiopharmaceutical agent that targets specific cells. 2. **Etoposide**: A chemotherapy drug that inhibits topoisomerase II. 3. **Melphalan**: A high-dose chemotherapy drug, an alkylating agent. 4. **Carboplatin**: A platinum-based chemotherapy drug that causes DNA cross-linking. 5. **Autologous Peripheral Stem Cell Transplantation**: A procedure where the patient's own stem cells are collected, preserved, and reinfused after the high-dose therapy. This combination serves as a conditioning regimen to kill cancer cells, followed by stem cell rescue to restore bone marrow function damaged by the intensive treatment. The stem cell transplantation process involves: - **Stem Cell Collection**: Mobilizing stem cells from bone marrow to the bloodstream using growth factors and collecting them via apheresis. - **Conditioning Regimen**: Administering the high-dose chemotherapy and 131I-MIBG. - **Stem Cell Reinfusion**: Thawing and reinfusing the collected stem cells. - **Recovery**: Allowing transplanted stem cells to engraft in the bone marrow and produce new blood cells, typically taking 2-3 weeks.
- Other names
- 131I-MIBG + etoposide + melphalan + carboplatin + Autologous Peripheral Stem Cell Transplantation131I-MIBG + CEM + APBSCT
02
Targets
DNANET (Norepinephrine Transporter)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 131I-MIBG + etoposide + melphalan + carboplatin + autologous peripheral stem cell transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 131I-MIBG + etoposide + melphalan + carboplatin + autologous peripheral stem cell transplantation.